Other molecular observations under preclinical investigation include TERT promoter alterations, which seems to be related to anaplastic progression, [2, 34, 35] apparently low rate of IDH1/IDH2 mutations and MGMT promoter hypermethylation, with differential diagnosis implications with Glioblastoma Multiforme (GBM) [36]. This evidence concerns the gene IDH1 and glioblastoma.